Efficacy of in‐class interleukin‐23 inhibitor switching: risankizumab following guselkumab failure in moderate‐to‐severe psoriasis treatment.

In a subset analysis of the patients who failed primary guselkumab treatment, PGA*BSA was 20-3 before risankizumab treatment and 8-6 after treatment, demonstrating a 57-6% decrease. Although patients who failed primary guselkumab treatment seem to have a less effective response to risankizumab than the patients who failed secondary treatment with guselkumab, there was still a notable reduction in PGA*BSA. For the patients who failed secondary treatment, the PGA*BSA was 36-0 before risankizumab treatment and 3-6 after treatment, showing a 90% average decrease. [Extracted from the article]